167 related articles for article (PubMed ID: 8432772)
1. Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods.
Ho KK; Valiontis E; Waters MJ; Rajkovic IA
J Clin Endocrinol Metab; 1993 Feb; 76(2):302-8. PubMed ID: 8432772
[TBL] [Abstract][Full Text] [Related]
2. Direct quantitation of growth hormone binding protein in human serum by a ligand immunofunctional assay: comparison with immunoprecipitation and chromatographic methods.
Rajkovic IA; Valiontis E; Ho KK
J Clin Endocrinol Metab; 1994 Mar; 78(3):772-7. PubMed ID: 8126156
[TBL] [Abstract][Full Text] [Related]
3. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
Weissberger AJ; Ho KK; Lazarus L
J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
[TBL] [Abstract][Full Text] [Related]
4. High affinity growth hormone binding protein in plasma of patients with acromegaly and the effect of octreotide treatment.
Roelen CA; Donker GH; Thijssen JH; Koppeschaar HP; Blankenstein MA
Clin Endocrinol (Oxf); 1992 Oct; 37(4):373-8. PubMed ID: 1483295
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
Fisker S; Kaal A; Montini M; Pedroncelli A; Pagani G; Orskov H
Eur J Endocrinol; 1997 Jan; 136(1):61-6. PubMed ID: 9037128
[TBL] [Abstract][Full Text] [Related]
7. Serum growth hormone-binding protein is unchanged in adult panhypopituitarism.
Davila N; Alcañiz J; Salto L; Estrada J; Barcelo B; Baumann G
J Clin Endocrinol Metab; 1994 Nov; 79(5):1347-50. PubMed ID: 7962328
[TBL] [Abstract][Full Text] [Related]
8. Blood growth hormone-binding protein levels in premenopausal and postmenopausal women: roles of body weight and estrogen levels.
Bondanelli M; Margutti A; Ambrosio MR; Plaino L; Cobellis L; Petraglia F; degli Uberti EC
J Clin Endocrinol Metab; 2001 May; 86(5):1973-80. PubMed ID: 11344194
[TBL] [Abstract][Full Text] [Related]
9. Guinea pig serum contains a specific high affinity growth hormone-binding protein with novel ligand specificity.
Ymer SI; Stevenson JL; Herington AC
Endocrinology; 1997 Sep; 138(9):3577-86. PubMed ID: 9275038
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a low affinity binding protein for growth hormone in rat serum.
Leung KC; Doyle N; Ho KK
Endocrinology; 2000 Jan; 141(1):138-45. PubMed ID: 10614632
[TBL] [Abstract][Full Text] [Related]
11. Measurement of growth hormone-binding protein in the rat by a ligand immunofunctional assay.
Leung KC; Millard WJ; Peters E; Markus I; Baumbach WR; Barnard R; Ho KK
Endocrinology; 1995 Feb; 136(2):379-85. PubMed ID: 7835268
[TBL] [Abstract][Full Text] [Related]
12. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone binding protein in the rat: effects of gonadal steroids.
Carmignac DF; Gabrielsson BG; Robinson IC
Endocrinology; 1993 Dec; 133(6):2445-52. PubMed ID: 8243263
[TBL] [Abstract][Full Text] [Related]
14. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women.
Kelly JJ; Rajkovic IA; O'Sullivan AJ; Sernia C; Ho KK
Clin Endocrinol (Oxf); 1993 Nov; 39(5):561-7. PubMed ID: 8252746
[TBL] [Abstract][Full Text] [Related]
15. Different modes of growth hormone (GH) administration do not change GH binding protein activity in man.
Ho KK; Jorgensen JO; Valiontis E; Waters MJ; Rajkovic IA; Christiansen JS
Clin Endocrinol (Oxf); 1993 Feb; 38(2):143-8. PubMed ID: 8435895
[TBL] [Abstract][Full Text] [Related]
16. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
Lissett CA; Shalet SM
J Clin Endocrinol Metab; 2003 Oct; 88(10):4668-72. PubMed ID: 14557438
[TBL] [Abstract][Full Text] [Related]
17. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
Bellantoni MF; Harman SM; Cho DE; Blackman MR
J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707
[TBL] [Abstract][Full Text] [Related]
18. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity.
Gleeson HK; Lissett CA; Shalet SM
J Clin Endocrinol Metab; 2005 Feb; 90(2):1061-7. PubMed ID: 15522943
[TBL] [Abstract][Full Text] [Related]
20. Plasma insulin-like growth factor-I and high affinity growth hormone-binding protein levels increase after two weeks of strenuous physical training.
Roelen CA; de Vries WR; Koppeschaar HP; Vervoorn C; Thijssen JH; Blankenstein MA
Int J Sports Med; 1997 May; 18(4):238-41. PubMed ID: 9231837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
